Kentaro Imai

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · New England Journal of Medicine · 2021 · 708 citations · Full text

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy

Hisashi Saji, Masahiro Tsuboi, Jun Matsubayashi et al. · Anti-Cancer Drugs · 2009 · 70 citations

Surgical Oncology, Perioperative Adjuvant Chemotherapy, Medicine +12

Positive EGFR mutation status is a risk of recurrence in pN0–1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis

Masaoki Ito, Yoshihiro Miyata, Yasuhiro Tsutani et al. · Lung Cancer · 2020 · 65 citations

Oncology, Retrospective Multi-center Analysis, Medicine +10